AR and prostate carcinoma: On the PROTACs against AR, Crews group used enzalutamide to optimally link to a VHL ligand and named the hybrid molecule ARCC‐4.67 They showed that ARCC‐4 induced the degradation of AR in not only all prostate cancer cell lines (VCaP, LNCaP, and 22Rv1) but also a breast cancer cell line (T47D).